Trial Profile
A prospective, non-randomised phase II study of trastuzumab and capecitabine in patients with HER2 expressing advanced pancreatic cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2010
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Trastuzumab (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Roche
- 28 Jun 2010 Status changed from completed to discontinued according to information reported at ASCO 2010.
- 08 Jun 2010 Study information reported at ASCO 2010.
- 20 Jun 2008 New trial record.